Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.32 |
| ▸ | ACP1 | P24666 | 1/20 | 0.31 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9458299 | 0.82 | MAOB (0.35) | S1PR1S1PR3NOTUMCNR1SLC6A2 | |
| SCHEMBL9458506 | 0.81 | MLYCD (0.47) | S1PR1S1PR3NOTUM | |
| SCHEMBL15207303 | 0.78 | MAOB (0.42) | — | |
| SCHEMBL9853038 | 0.76 | NOTUM (0.34) | NOTUMTAS2R14 | |
| SCHEMBL9458604 | 0.75 | CYP2A6 (0.40) | S1PR1S1PR3NOTUMTAS2R14SLC6A2 | |
| SCHEMBL9853033 | 0.74 | SLC6A4 (0.38) | PARK7SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3591051 | 0.74 | IDO1 (0.41) | S1PR1S1PR3NOTUMCNR1PARK7 | |
| SCHEMBL29738521 | 0.74 | IDO1 (0.41) | S1PR1S1PR3NOTUMCNR1PARK7 | |
| SCHEMBL9457966 | 0.74 | CYP19A1 (0.37) | S1PR1S1PR3NOTUMSLC6A2SLC6A4 | |
| SCHEMBL7561792 | 0.73 | TSHR (0.48) | SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5208259-A | Lipoxygenase enzyme inhibitors | IMPERIAL CHEMICAL INDUSTRIES (GB) | 1993-05-04 | — | — | US | disclosed |